Women's Health New Genetics (WHNG)

Takes the Canadian Biotechnology Strategy to tak for its claim to support sustainable development. Proposes a set of criteria for truly sustainable development, and evaluates the CBS in light of these criteria by focusing on the CBS's claims relating to agricultural biotechnology and bioengineered foods. Demonstrates that the risks of bioengineered foods are ignored by the CBS in its inflated listing of potential benefits.

Examines the Canadian Biotechnology Strategy and the genetic technologies it promotes to be both a contributor to, and signifer of, the changing nature of the state.

Argues that the ethical values proposed by the Canadian Biotechnology Strategy are untenable, being premised on faith in the value of genetically engineered (GE) crops and foods.

Looks at the inconsistencies between the promises made in the name of biotechnology and the lived experience of most of the world's women.

Explains the history of the Working Group on Women, Health and the New Genetics, and the goals of the national Strategic Workshop held on February 11 and 12, 2000 at York University in Toronto, Ontario.

Examines the challenge of genetics in relation to breast cancer. Introduces a new treatment protocol for breast cancer, herceptin or trastuzumab. Looks at its challenges, including its high price.

Outlines some of the contradictory ways that wealth and health interact in the Canadian Biotechnology Strategy.

Examines the new genetics and its potential impact on women's health.

Outlines the links that exist between cultural diversity and biological diversity.

Outlines research priorities which are intended as contributions to a strategy for building broader public debate.